Is Your Patient Eligible?

Prostate cancer patients Genomic Prostate Score 

Your patients with clinically low- or favorable intermediate-risk prostate cancer might be candidates for the Oncotype DX Genomic Prostate Score (GPS) test.


The Oncotype DX GPS assay is for men who have:

  • Had a prostate biopsy within the last three years.
  • Not started definitive treatment (e.g. surgery or radiation).
  • Clinically low- and favorable-intermediate-risk prostate cancer—meeting the criteria for National Comprehensive Cancer Network® (NCCN®) very-low, low-, or intermediate-risk disease.



Very Low

Has all of the following:
  • T1c
  • Grade Group 1
  • PSA <10 ng/mL
  • Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core
  • PSA density <0.15 ng/mL/g
  • Low

    Has all of the following but does not qualify for very low risk:
  • T1-T2a
  • Grade Group 1
  • PSA <10 ng/mL
  • Intermediate

    Has all of the following:
  • No high-risk group features
  • No very-high-risk group features
  • Has one or more intermediate risk factors (IRF):
  • T2b-T2c
  • Grade Group 2 or 3
  • PSA 10-20 ng/mL
  • Favorable intermediate

    Has all of the following:
  • 1 IRF
  • Grade Group 1 or 2
  • <50% biopsy cores positive
  • Unfavorable intermediate

    Has one or more of the following:
  • 2 or 3 IRFs
  • Grade Group 3
  • ≥50% biopsy cores positive
  • When to order the test

    Because the goal of the Oncotype DX GPS assay is to facilitate management planning for prostate cancer patients, the best time to order the test is shortly after biopsy and before initial treatment decisions have been made. Ordering is easy, and the test can be run on a small sample from a recent biopsy.

    Insurance and financial assistance

    The Oncotype DX GPS test is covered by Medicare (for NCCN very low-, low- and favorable intermediate-risk cancer). Private insurance coverage varies. To help patients navigate insurance and other payment options for Oncotype DX testing, Exact Sciences offers the Genomic Access Program (GAP) and detailed information about financial assitance. Learn more about insurance coverage and financial assistance by contacting customer service at 866-ONCOTYPE (866-662-6897).

    National Comprehensive Cancer Network® (NCCN) and NCCN® are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

    Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 18, 2020. To view the most recent and complete version of the guideline, go online to

    NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

    Stay in Touch

    Have a specific question? Want to keep up with our latest news? We're here for you.

    Contact Us
    Making cancer care smarter.®

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.